Skip to main content

Table 3 Cox proportional hazards regression analysis for progression-free survival

From: The prognostic significance of pretreatment squamous cell carcinoma antigen levels in cervical cancer patients treated by concurrent chemoradiation therapy and a comparison of dosimetric outcomes and clinical toxicities between tomotherapy and volumetric modulated arc therapy

Variable

HR

95% CI

P value

Age ≥ 60 years

1.90

0.84–4.28

0.122

OTT of RT > 61 days

1.61

0.69–3.78

0.273

T3 or T4 disease

2.72

1.30–5.71

0.008

N1 or N2 disease

2.55

1.15–5.63

0.021

Pretreatment SCC Ag > 10 ng/mL

2.20

1.03–4.71

0.041

Post-treatment SCC Ag > 1.5 ng/mL

2.01

0.82–4.96

0.129

EQD2 of Point A ≥ 81 Gy

1.39

0.65–2.97

0.403

RT techniquea

  

0.423

 VMAT

0.53

0.13–2.08

0.359

 Tomotherapy

0.91

0.25–3.33

0.889

  1. HR hazard ratio, CI confidence interval, OTT overall treatment time, RT radiation therapy, SCC Ag squamous cell carcinoma antigen, EQD2 equivalent dose in 2-Gy fractions, VMAT volumetric modulated arc therapy
  2. aReference category: 3DCRT, three-dimensional conformal radiation therapy